



PrescribelT Baseline Study

Dr. Neil McEvoy

March 21, 2019





Contents

Та	ble of contents	2
1	Background to the Study 1.1 Overall purpose	3
2	Phase 2 Baseline Findings 2.1 Selected sites	2
3	Anticipating Phase 3 Increments 3.1 Survey extension	2
4	Reference Materials	2

1 Background to the Study

The baseline study reported here is the second phase of a three phase project intended to gather evidence of the benefits of PrescribelT in prescribing and dispensing medications.

1.1 Overall purpose

The overall purpose of the project is to gather evidence of the benefits of PrescribelT.

1.2 Summary of Phase 1 Workflow

The first phase examined workflow at selected physician offices and dispenser outlets. The study identified patterns of flow, and exposed key processes at which changes due to PrescribelT might contribute improvements.

1.3 Goals of Phase 2 Baseline

The goal of the second phase is to establish baseline indicators close to the introduction of PrescribeIT as measures against which future changes could be compared.

1.4 Design of Phase 2 Baseline

The phase uses indicator sets developed in light of the findings of the initial workflow phase. Each is tailored to the specifics of dispensers and prescribers repectively.


The indicators were assembled as a secure website designed for secure yet easy access.

The indicators are shown in the following tables

2 Phase 2 Baseline Findings

Sepal.Length	Sepal.Width	Petal.Length	Petal.Width	Species
5.10	3.50	1.40	0.20	setosa
4.90	3.00	1.40	0.20	setosa
4.70	3.20	1.30	0.20	setosa
4.60	3.10	1.50	0.20	setosa
5.00	3.60	1.40	0.20	setosa
5.40	3.90	1.70	0.40	setosa
4.60	3.40	1.40	0.30	setosa
5.00	3.40	1.50	0.20	setosa
4.40	2.90	1.40	0.20	setosa
4.90	3.10	1.50	0.10	setosa
5.40	3.70	1.50	0.20	setosa
4.80	3.40	1.60	0.20	setosa
4.80	3.00	1.40	0.10	setosa
4.30	3.00	1.10	0.10	setosa
5.80	4.00	1.20	0.20	setosa
5.70	4.40	1.50	0.40	setosa
5.40	3.90	1.30	0.40	setosa
5.10	3.50	1.40	0.30	setosa
5.70	3.80	1.70	0.30	setosa
5.10	3.80	1.50	0.30	setosa

Table 1: List of sites



2.1 Selected sites

The following sites were selected for participation by CHI Prescribers:

- 2.2 Prescribers
- 2.3 Dispensers
- 2.4 Salient findings
- 3 Anticipating Phase 3 Increments
- 3.1 Survey extension
- 3.2 Potential findings
- 4 Reference Materials